glutathione l cystine 🎉NEW DROP 🎉 💗 REDUCED GLUTA plus L- ใส ไบร์ท ลืมหมอง จาก SOLVE กลูต้าฟอร์มใหม่ สูตรงานวิจัย* 🧬 Synergistic Formulation ผสาน 3 องค์ประกอบที่ทำงานประสานกัน 💗 Reduced 250 mg กลูต้าไธโอน รูปแบบที่พร้อมใช้งาน (Active Form) ✓ช่วย Transferproof Lipstick Understanding the Ingredients L Scent:Unscented Collagen 6600mg Vitamin C

glutathione l cystine 🎉NEW DROP 🎉 💗 REDUCED GLUTA plus L- ใส ไบร์ท ลืมหมอง จาก SOLVE กลูต้าฟอร์มใหม่ สูตรงานวิจัย* 🧬 Synergistic Formulation ผสาน 3 องค์ประกอบที่ทำงานประสานกัน 💗 Reduced 250 mg กลูต้าไธโอน รูปแบบที่พร้อมใช้งาน (Active Form) ✓ช่วย Transferproof Lipstick Understanding the Ingredients L Scent:Unscented Collagen 6600mg Vitamin C

Collagen 6600mg Vitamin C | Made in Singapore –

Liposomal glutathione focuses on cellular support rather than surface treatment alone

Transferproof Lipstick

Scent:Unscented

⸻ 🔵 Population ▪ Adults with obesity or overweight + weight-related comorbidities ▪ Primarily obesity population ▪ Mean baseline weight ≈ 110–115 kg ▪ Duration ≈ 84 weeks ⸻ 🟢 Study Design ▪ Phase 3 randomized, open-label head-to-head trial ▪ ~800 participants ▪ Once-weekly subcutaneous injections ▪ Full target doses compared ▪ Primary objective: Demonstrate non-inferiority of CagriSema ⸻ 🟡 Treatments Compared ▪ CagriSema Combination of: • Cagrilintide (amylin analogue) • Semaglutide (GLP-1 receptor agonist) Target dose: 2.4 mg / 2.4 mg weekly ▪ Tirzepatide • Tirzepatide Dual GIP + GLP-1 receptor agonist Target dose: 15 mg weekly ⸻ 🟣 Primary Efficacy — Weight Loss at ~84 Weeks 🔹 On-treatment (full adherence) ▪ CagriSema ≈ 23.0% ▪ Tirzepatide ≈ 25.5% 🔹 Treatment-policy (all randomized) ▪ CagriSema ≈ 20.2% ▪ Tirzepatide ≈ 23.6% ⸻ 🔵 Primary Endpoint Outcome ▪ Non-inferiority of CagriSema NOT achieved ▪ Tirzepatide demonstrated superior weight reduction ▪ Trial considered negative for its primary objective ⸻ 🟢 Safety Profile ▪ Predominantly gastrointestinal adverse events ▪ Mostly mild–moderate ▪ Consistent with incretin-based therapies ▪ No major unexpected safety signals reported ⸻ 🟡 Critical Appraisal ▪ Open-label design (no blinding) ▪ Expectation & behavioral bias possible ▪ Flexible titration (not all reached maximal dose) ▪ On-treatment vs ITT differences notable ▪ No cardiovascular endpoint data ▪ Long-term durability unknown ▪ High-BMI population may limit generalizability ⸻ 🟣 REDEFINE Program Context ▪ REDEFINE-1 → Obesity ▪ REDEFINE-2 → Obesity + metabolic disease ▪ REDEFINE-3 → Obesity + cardiovascular disease ▪ REDEFINE-4 → Head-to-head vs Tirzepatide ⸻ 🔵 Clinical Bottom Line ▪ Large, rigorous head-to-head obesity trial ▪ Tirzepatide achieved greater mean weight loss ▪ CagriSema still delivered very substantial reductions (~20–23%) ▪ Both represent highly potent anti-obesity pharmacotherapy ▪ Final positioning will depend on CV outcomes, durability, access, and real-world data ⸻ 📌 The obesity therapeutic era is accelerating — and comparative effectiveness data is now shaping real clinical decisions

Understanding the Ingredients L